# A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00685841** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 717 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Arformoterol tartrate inhalation solution
- **DRUG:** Arformoterol tartrate inhalation solution
- **DRUG:** Arformoterol tartrate inhalation solution
- **DRUG:** Salmeterol MDI
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00685841
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2003-06
- **Final completion:** 2003-06
- **Target enrollment:** 717 (ACTUAL)
- **Last updated:** 2012-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00685841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00685841, "A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00685841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*